Filtered By:
Source: Cardiovascular Therapeutics
Condition: Bleeding

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy
ConclusionsIschemic stroke and intestinal bleeding may consecutively occur shortly after stopping dabigatran. Coagulation parameters may remain abnormal even two days after discontinuation of dabigatran. Dabigatran should be applied with caution in elderly patients with renal insufficiency who also take drugs, which enhance the absorption of dabigatran.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - September 23, 2013 Category: Cardiology Authors: Josef Finsterer, Claudia Stöllberger, Gernot Paul, Adam Bastovansky Tags: Short Communication Source Type: research

Warfarin prescription in patients with non ‐valvular atrial fibrillation and one non‐gender related risk factor (CHA2DS2VASc 1 or 2): a treatment dilemma
ConclusionWe found an elevated risk of major bleeding and intracranial haemorrhage in AF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - October 1, 2017 Category: Cardiology Authors: Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Emilia Antonucci, Francesco Marongiu, Daniela Poli, Sophie Testa, Armando Tripodi, Gualtiero Palareti, Vittorio Pengo Tags: Original Research Article Source Type: research

Warfarin prescription in patients with nonvalvular atrial fibrillation and one non –gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma
ConclusionWe found an elevated risk of major bleeding and intracranial hemorrhage in NVAF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals.
Source: Cardiovascular Therapeutics - November 11, 2017 Category: Cardiology Authors: Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Emilia Antonucci, Francesco Marongiu, Daniela Poli, Sophie Testa, Armando Tripodi, Gualtiero Palareti, Vittorio Pengo Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Non Vitamin K Oral Anticoagulants versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments yield Novel Insights
ConclusionsFor the primary‐outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced haemorrhagic‐stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential haemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary‐outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 4, 2016 Category: Cardiology Authors: Cyrus R Kumana, Bernard M Y Cheung, David C W Siu, Hung‐Fat Tse, Ian J Lauder Tags: Unsolicited Review Source Type: research

Non‐vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
ConclusionsFor the primary outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced hemorrhagic stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential hemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Cyrus R. Kumana, Bernard M.Y. Cheung, David C.W. Siu, Hung‐Fat Tse, Ian J. Lauder Tags: Unsolicited Review Source Type: research

Clinical and Economic Outcomes among Elderly Myocardial Infarction Survivors in the United States
ConclusionsRisks of mortality and cardiovascular events remain high in a Medicare population surviving >1 year after a MI. Continuing healthcare costs are doubled over pre‐MI levels up to five years after an MI. Secondary prevention measures beyond the acute post‐MI period may be indicated to reduce risk and cost in this chronic disease phase.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - July 31, 2016 Category: Cardiology Authors: Erru Yang, Michael Stokes, Saga Johansson, Carl Mellstr öm, Elizabeth Magnuson, David J. Cohen, Phillip Hunt Tags: Original Research Article Source Type: research

Optimal duration of dual antiplatelet therapy after drug eluting stents: Meta‐analysis of randomized trials
ConclusionDAPT continued beyond 6 months after second generation DES implantation, decreases stent thrombosis and myocardial infarction, but increases major bleeding and all‐causes mortality compared to shorter DAPT (aspirin alone). There was no difference in cardiac mortality or stroke.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - May 25, 2015 Category: Cardiology Authors: Elsayed Abo‐salem, Said Alsidawi, Hina Jamali, Mohamed Effat, Tarek Helmy Tags: Original Research Article Source Type: research

Optimal Duration of Dual Antiplatelet Therapy after Drug‐Eluting Stents: Meta‐Analysis of Randomized Trials
ConclusionDAPT continued beyond 6 months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all‐causes mortality compared to shorter DAPT (aspirin alone). There was no difference in cardiac mortality or stroke.
Source: Cardiovascular Therapeutics - September 11, 2015 Category: Cardiology Authors: Elsayed Abo‐salem, Said Alsidawi, Hina Jamali, Mohamed Effat, Tarek Helmy Tags: Original Research Article Source Type: research

Warfarin persistence among atrial fibrillation patients – why is treatment ended?
ConclusionsAlthough persistence to warfarin among AF patients proves higher than previously reported, there is room for improvement since half of the discontinuers have questionable reasons for treatment stop and the majority of them receive no other efficient stroke prophylaxis.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - August 26, 2016 Category: Cardiology Authors: Fredrik Bj örck, E k Agnes, Lars Johansson, Anders Själander Tags: Original Research Article Source Type: research

Anticoagulation in Patients with Dilated Cardiomyopathy, Low Ejection Fraction, and Sinus Rhythm: Back to the Drawing Board
Summary Heart failure patients present an important thrombo‐embolic risk, including symptomatic or silent peripheral arterial embolism, pulmonary embolism, and stroke. Patients in sinus rhythm who have concomitant depressed (<35%) left ventricular ejection fraction have a 4% rate of embolic events. Several prospective randomized trials of anticoagulation in this group of patients were either underpowered or had a short period of follow‐up. Even though in two studies warfarin had a slight advantage over aspirin (in the WATCH and WARCEF trials), it was at the cost of an increased risk in major hemorrhage. To decrease ...
Source: Cardiovascular Therapeutics - September 12, 2013 Category: Cardiology Authors: Alexandru Nicolae Mischie, Valentin Chioncel, Ionel Droc, Crina Sinescu Tags: Short communication Source Type: research

Bivalirudin use and one‐month outcome in the context of contemporary antiplatelet treatment: Insights from the Greek Antiplatelet Registry
ConclusionsIn a ‘real life’, contemporary antiplatelet treatment registry, clinical, laboratory and logistic factors affect bivalirudin's choice, while there are no differences in one‐month outcome between bivalirudin and no bivalirudin treated patients.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - February 1, 2014 Category: Cardiology Authors: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Spyridon Deftereos, George Sitafidis, Ioannis Kanakakis, Michalis Hamilos, George Karayannis, Christos Angelidis, Katerina Stavrou, Manolis Vavuranakis, John A. Goudevenos, Christodoulos Stefanadis, Tags: Original Research Article Source Type: research

The ‘Dual‐Pathway’ Strategy After Acute Coronary Syndrome: Rivaroxaban and Anti‐platelet Agents in the ATLAS ACS 2‐TIMI 51 Trial
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - June 1, 2014 Category: Cardiology Authors: Marc Cohen, Deepa Iyer Tags: Unsolicited Review Source Type: research

The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial
Summary Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long‐term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination with a platelet P2Y12 inhibitor (dual antiplatelet therapy [DAPT]) has become the clinically accepted antithrombotic prophylaxis for patients post‐ACS. Historically, studies assessing the utility of adding oral anticoagulants (OACs) have not demonstrated a clinical benefit with regard to acceptabl...
Source: Cardiovascular Therapeutics - September 9, 2014 Category: Cardiology Authors: Marc Cohen, Deepa Iyer Tags: Review Source Type: research

Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients With Atrial Fibrillation
ConclusionsOlder adults with atrial fibrillation rarely have absolute contraindications to oral anticoagulation therapy. Among patients without contraindications, most appeared to be eligible for any anticoagulant, and relatively high‐risk features appeared not to influence warfarin use.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2015 Category: Cardiology Authors: Benjamin A. Steinberg, Melissa A. Greiner, Bradley G. Hammill, Lesley H. Curtis, Emelia J. Benjamin, Susan R. Heckbert, Jonathan P. Piccini Tags: Original Research Article Source Type: research

The burden of major adverse cardiac events and antiplatelet prevention in patients with coronary or peripheral arterial disease
ConclusionDespite gaps in the literature, this assessment showed that MACE's risk is substantial among CAD or PAD patients and that the use of preventive therapies is suboptimal. Development of additional preventive therapies for these patients is warranted.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - December 1, 2015 Category: Cardiology Authors: Hanane Khoury, Louis Lavoie, Sharon Welner, Kerstin Folkerts Tags: Unsolicited Review Source Type: research